Titlebook: Novel therapeutic approaches for gastrointestinal malignancies; Ganji Purnachandra Nagaraju,Sujatha Peela Book 2020 The Editor(s) (if appl

非实体

Recent Development in the Biomarkers for the Gastric Cancer, PD-L2), fibroblast growth factor receptor (FGFR), and mTOR. There are some newly diagnosed biomarkers as well such as instability of microsatellite, mesenchymal–epithelial transition (MET), and differences in microRNA. Detection, identification, and validation of diagnostic, predictive, and pharmac

终端

粗鲁性质

An Intergenic Variant rs4779584 Between SCG5 and GREM1 Contributes to the Increased Risk of Colorec with 26 different studies comprising 25,469 CRC cases and 32,745 controls were finally considered for meta-analysis. Overall, a positive association of rs4779584 polymorphism with CRC risk was found in all genetic models (allelic model: OR = 1.13; 95% CI 1.08–1.18; . = <0.001; .: 53%; dominant mode

你正派

博识

Pancreatic Ductal Adenocarcinoma and Type 2 Diabetes Mellitus: Distant Relatives or the Close Ones?ads to PDAC, mediated by various factors like redox stress, inflammation, insulin resistance, and β-cell mass degeneration. At the end, this chapter focuses on the therapeutic approach for PDAC, taking into account the two efficient branches of medicine which have recently gained much of attention,

Tartar

Corroborate

2662-2688 atically investigates novel theranostics approaches using nanotechnology for the detection, diagnosis, and personalized treatment of GI malignancies..978-981-15-5473-5978-981-15-5471-1Series ISSN 2662-2688 Series E-ISSN 2662-2696

使迷醉

Novel therapeutic approaches for gastrointestinal malignancies

可用

Diagnostics and Therapeutic Advances in GI Malignancieshttp://image.papertrans.cn/n/image/668477.jpg

visual-cortex